Compositions and methods for treatment of cervical cancer
View Patent ↗The present invention provides methods of treating, protecting against, and inducing an immune response against cervical cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and an E7 and/or E6 antigen. The present invention also provides methods for inducing an anti-E7 response in a human subject and treating HPV-mediated diseases, disorders, and symptoms comprising administration of the recombinant Listeria strain.
1. A method of treating a late stage cervical cancer in a human patient having said late stage cancer, comprising the step of administering to said patient a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant polypeptide comprising an N-terminal fragment of an LLO protein fused to a Human Papilloma Virus (HPV) E7 antigen, whereby said recombinant Listeria strain induces an immune response against said E7 antigen, thereby treating a late stage cervical cancer in a human patient.
2. The method of claim 1 , wherein said N-terminal fragment of an LLO protein comprises SEQ ID No: 1.
3. The method of claim 1 , wherein said recombinant Listeria strain is administered to said human patient at a dose of 1×10 9 -3.31×10 10 organisms.
4. The method of claim 1 , wherein said recombinant Listeria strain is a recombinant Listeria monocytogenes strain.
5. The method of claim 1 , wherein said recombinant Listeria strain has been passaged through an animal host, prior to the step of administering.
6. The method of claim 1 , wherein said recombinant polypeptide is expressed by said recombinant Listeria strain.
7. The method of claim 1 , wherein said recombinant Listeria strain comprises a plasmid that encodes said recombinant polypeptide.
8. The method of claim 7 , wherein said plasmid comprises a gene encoding a bacterial transcription factor.
9. The method of claim 7 , wherein said plasmid further comprises a gene encoding a metabolic enzyme.
10. The method of claim 1 , further comprising the step of boosting said human patient with said recombinant Listeria strain.
11. The method of claim 1 , further comprising the step of inoculating said human patient with an immunogenic composition that comprises or directs expression of said E7 antigen.
12. The method of claim 1 , wherein said recombinant Listeria strain has been stored in a frozen, dried or lyophilized cell bank.
13. The method of claim 12 , wherein said recombinant Listeria strain exhibits viability upon thawing or reconstitution of greater than 90%.
14. The method of claim 1 , wherein said late stage cervical cancer is stage IV.
15. The method of claim 14 , wherein said stage IV is stage IVB.